These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16086891)

  • 1. Evaluation of yellow fever vaccination centers in Canada.
    Labelle C; Macpherson DW
    J Travel Med; 2005; 12(4):180-3. PubMed ID: 16086891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standards of yellow fever vaccination and travel medicine practice in the Republic of Ireland: A questionnaire-based evaluation.
    Noone P; Hamza M; Tang J; Flaherty G
    Travel Med Infect Dis; 2015; 13(5):409-14. PubMed ID: 26148651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of travel medicine practice by yellow fever vaccination centers in England, Wales, and Northern Ireland.
    Boddington NL; Simons H; Launders N; Gawthrop M; Stillwell A; Wong C; Mathewson J; Hill DR
    J Travel Med; 2012; 19(2):84-91. PubMed ID: 22414032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of yellow fever vaccination practice in England.
    Bryant N; Tucker R; Simons H; Bailey S; Mathewson J; Lea G; Hill DR
    J Travel Med; 2008; 15(5):287-93. PubMed ID: 19006500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality improvement in travel medicine: a programme for yellow fever vaccination centres in England, Wales and Northern Ireland.
    Boddington NL; Simons H; Launders N; Hill DR
    Qual Prim Care; 2011; 19(6):391-8. PubMed ID: 22340901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking yellow fever vaccinator approval and renewal with training in travel medicine in New Zealand.
    O'Brien B; Leggat PA
    Travel Med Infect Dis; 2010 Jul; 8(4):210-2. PubMed ID: 20970723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.
    Jentes ES; Poumerol G; Gershman MD; Hill DR; Lemarchand J; Lewis RF; Staples JE; Tomori O; Wilder-Smith A; Monath TP;
    Lancet Infect Dis; 2011 Aug; 11(8):622-32. PubMed ID: 21798462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractional dosing of yellow fever vaccine during shortages: perspective from Canada.
    Teitelbaum P; Bui YG; Libman M; McCarthy A
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346564
    [No Abstract]   [Full Text] [Related]  

  • 9. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015.
    Staples JE; Bocchini JA; Rubin L; Fischer M;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):647-50. PubMed ID: 26086636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unpredictable checks of yellow fever vaccination certificates upon arrival in Tanzania.
    Schönenberger S; Hatz C; Bühler S
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27296582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow Fever Vaccine Administration at Global TravEpiNet (GTEN) Clinics during a Period of Limited Vaccine Availability in the United States, 2017-2018.
    Walker AT; Gershman MD; Rao SR; LaRocque RC; Ryan ET;
    Am J Trop Med Hyg; 2021 Jan; 104(3):1079-1084. PubMed ID: 33534766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to yellow fever travel vaccination centres in England, Wales, and Northern Ireland: A geographical study.
    Petersen J; Simons H; Patel D
    Travel Med Infect Dis; 2017; 18():24-29. PubMed ID: 28698027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late vaccination against yellow fever of travelers visiting endemic countries.
    Krief I; Goldblatt JG; Paz A; Potasman I
    Travel Med Infect Dis; 2006 Mar; 4(2):94-8. PubMed ID: 16887731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
    Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
    J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No booster dose for yellow fever vaccination: what are the consequences for the activity of vaccination in travel clinics?
    Wyplosz B; Leroy JP; Derradji O; Consigny PH
    J Travel Med; 2015; 22(2):140-1. PubMed ID: 25384441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination Challenges in Confronting the Resurgent Threat From Yellow Fever.
    Chen LH; Hamer DH
    JAMA; 2017 Nov; 318(17):1651-1652. PubMed ID: 28983553
    [No Abstract]   [Full Text] [Related]  

  • 17. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002.
    Cetron MS; Marfin AA; Julian KG; Gubler DJ; Sharp DJ; Barwick RS; Weld LH; Chen R; Clover RD; Deseda-Tous J; Marchessault V; Offit PA; Monath TP
    MMWR Recomm Rep; 2002 Nov; 51(RR-17):1-11; quiz CE1-4. PubMed ID: 12437192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017.
    Gershman MD; Angelo KM; Ritchey J; Greenberg DP; Muhammad RD; Brunette G; Cetron MS; Sotir MJ
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(17):457-459. PubMed ID: 28472025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow fever vaccination centers: concurrent vaccinations and updates on mosquito biology.
    Arya SC; Agarwal N
    Travel Med Infect Dis; 2012 Sep; 10(5-6):257-8. PubMed ID: 22613468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.